Navigation Links
Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
Date:2/9/2009

CALGARY, Feb. 9 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotech company developing stem cell-mobilizing pharmaceuticals, announced today that it has filed with the European Competent Authority in Seville, Spain, a Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan. ORC utilized the regulatory expertise and experience of Kinesis Pharma BV (Breda, Netherlands) to develop the clinical trial submission. The planned study is to be conducted by InPEC BV (Breda, Netherlands) at their clinical trial site in Malaga, Spain.

Dr. Thomas Ichim, Chairman of ORC's Scientific Advisory Board commented "HYC750 possesses a very favourable pharmacological and pharmaceutical profile and is an excellent candidate for aggressive and rapid clinical development."

"Filing the requisite regulatory documentation with the European authorities to initiate our Phase I clinical trial was a major accomplishment for our company and represents Orcrist's most important milestone thus far," said Dr. Brett Schönekess, President and CEO of Orcrist. "We are thrilled with the expertise and professionalism provided by both Kinesis and InPEC, and are very excited to see the HYC750 clinical program move forward. Our clinical goal is to confirm the safety profile of HYC750 and to see a clear illustration of its stem cell mobilization properties, which would support its future development as a treatment for chemotherapy-related blood cell depletion."

"We are very honored to be chosen by Orcrist to coordinate and perform their Phase I study with HYC750 and we look forward to the future initiation of the trial" commented Dr. Ronald van der Geest, Chief Business Officer of InPEC BV. "Orcrist, Kinesis, and InPEC have worked as a team on this project, and I believe a very strong clinical trial application has been submitted."

About Orcrist Bio Inc.

Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists. ORC's lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related white blood cell depletion. Orcrist is actively looking to add to its pipeline exploring the innate properties of HYC750 and its effects on stem cells, as well as through in-licensing opportunities of other products with clear market potential. ORC is located in Calgary, Alberta. The company is financed by its founders and by private investors.

About Kinesis Pharma BV

Kinesis Pharma BV is an independent, privately owned company based in The Netherlands. Kinesis aims to facilitate a fast and high quality drug development process in close collaboration with the preclinical and clinical R&D departments of pharmaceutical and biotech companies through consultancy and contract research services. Currently, Kinesis employs about 55 people, many of them with extensive industrial and/or regulatory experience.

About InPEC BV

InPEC BV is a clinical CRO that focuses on the execution of Phase I and IIa clinical trials. Its professional and experienced team, and state of the art facilities, embedded within the care of a private hospital with an ICU unit on the same floor, guarantee maximum safety for the full range of clinical pharmacology studies. Electronic data processing procedures are in place to enable high-quality and efficient data processing on-site. InPEC's head office is located in the Netherlands. Clinical facilities are located in Malaga, Spain.


'/>"/>
SOURCE Orcrist Bio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tigris Pharmaceuticals Files IND Application for GGTI-2418
2. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
3. Stem Cell Innovations, Inc., Files New Patent Application
4. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
8. Sangui BioTech International, Inc. Files Remaining Reports
9. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
10. China-Biotics, Inc. Files Application for Nasdaq Listing
11. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):